{
    "root": "2f164c66-4cd2-e2cf-e063-6394a90afb6c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fondaparinux Sodium",
    "value": "20250226",
    "ingredients": [
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "FONDAPARINUX SODIUM",
            "code": "X0Q6N9USOZ"
        }
    ],
    "indications": "Fondaparinux sodium injection is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. (1.1) Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin. ( 1.2 , 1.3 )",
    "contraindications": "For subcutaneous use, do not mix with other injections or infusions. ( 2.1 ) Prophylaxis of deep vein thrombosis: Fondaparinux sodium 2.5 mg subcutaneously once daily after hemostasis has been established. The initial dose should be given no earlier than 6 to 8 hours after surgery and continued for 5 to 9 days. For patients undergoing hip fracture surgery, extended prophylaxis up to 24 additional days is recommended. ( 2.2 , 2.3 ) Treatment of deep vein thrombosis and pulmonary embolism: Fondaparinux sodium 5 mg (body weight <50 kg), 7.5 mg (50 to 100 kg), or 10 mg (>100 kg) subcutaneously once daily. Treatment should continue for at least 5 days until INR 2 to 3 achieved with warfarin sodium.( 2.4 )",
    "warningsAndPrecautions": "Fondaparinux sodium injection, USP is available in the following strengths and package sizes:\n                  2.5 mg fondaparinux sodium injection, USP in 0.5 mL single-dose prefilled syringe, affixed with a 27-gauge x ½-inch needle and an automatic needle protection system with white plunger rod.\n                  NDC 0781-3443-12 2 Single Unit Syringes\n  \n                     \nNDC 0781-3443-95 10 Single Unit Syringes\n \n                  5 mg fondaparinux sodium injection, USP in 0.4 mL single-dose prefilled syringe, affixed with a 27-gauge x ½-inch needle and an automatic needle protection system with white plunger rod.\n                  NDC 0781-3454-12 2 Single Unit Syringes\n  \n                     \nNDC 0781-3454-95 10 Single Unit Syringes\n \n                  7.5 mg fondaparinux sodium injection, USP in 0.6 mL single-dose prefilled syringe, affixed with a 27-gauge x ½-inch needle and an automatic needle protection system with white plunger rod.\n                  NDC 0781-3465-12 2 Single Unit Syringes\n  \n                     \nNDC 0781-3465-95 10 Single Unit Syringes\n \n                  10 mg fondaparinux sodium injection, USP in 0.8 mL single-dose prefilled syringe, affixed with a 27-gauge x ½-inch needle and an automatic needle protection system with white plunger rod.\n                  NDC 0781-3476-12 2 Single Unit Syringes\n  \n                     \nNDC 0781-3476-95 10 Single Unit Syringes\n \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].\n                  Discard unused portion.\n                  PHARMACIST: Dispense a Patient Information Leaflet with each prescription.",
    "adverseReactions": "Fondaparinux sodium injection is contraindicated in the following conditions:\n                  \n                     Severe renal impairment (creatinine clearance [CrCl] <30 mL/min) [see \n   Warnings and Precautions \n                        \n                           (5.3)\n                        \n                         and Use in Specific Populations \n                        \n                           (8.6)\n                        ].\n  \n                     Active major bleeding.\n                     Bacterial endocarditis.\n                     Thrombocytopenia associated with a positive \n   in vitro test for anti-platelet antibody in the presence of fondaparinux sodium.\n  \n                     Body weight <50 kg (venous thromboembolism [VTE] prophylaxis only) [see \n   Warnings and Precautions \n                        \n                           (5.4)\n                        ].\n  \n                     History of serious hypersensitivity reaction (e.g., angioedema, anaphylactoid/anaphylactic reactions) to fondaparinux sodium."
}